Change in management at Genmab
This article was originally published in Scrip
Genmab (Denmark) has announced that Dr Claus Møller is to step down from his position as executive vice-president and chief operating officer. He will remain available to the company as Development Advisor for the remainder of 2008. The COO position at Genmab will be discontinued and Dr Møller's responsibilities will be folded into the R&D department which has already been consolidated under the direction of Professor Jan van de Winkel, president of R&D and chief scientific officer.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.